Drug intelligence / Profile preview

paroxetine + quetiapine

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

Paroxetine + quetiapine is a combination of two pharmaceutical drugs, paroxetine and quetiapine, used together primarily in psychiatric practice. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels by inhibiting its reuptake, thereby exerting antidepressant and anxiolytic effects. Quetiapine is an atypical antipsychotic with antagonistic activity at multiple neurotransmitter receptors including serotonergic (5-HT2A), dopaminergic (D2), histaminergic (H1), and adrenergic receptors. This combination has been studied as an augmentation strategy for patients with generalized anxiety disorder who remain symptomatic after initial SSRI therapy; however, evidence does not support significant additional benefit from adding quetiapine to ongoing paroxetine treatment in this context[2][3]. The combination may increase the risk of additive central nervous system depression and impairment of judgment or psychomotor skills[1].

02

Targets

DRD2 (Dopamine D2 Receptor)SERT (Sodium-dependent serotonin transporter)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on paroxetine + quetiapine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paroxetine + quetiapine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call